Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology has reported the positive results of the company's proprietary buccal insulin spray product Oral-lyn.
Subscribe to our email newsletter
The study enrolled 31 subjects diagnosed with impaired glucose tolerance (IGT), with a with a mean age of 52 years and a body mass index of 33.
The patients received Generex Oral-lyn in equal doses before and 30 minutes after drinking 75 grams of glucose in a standard oral glucose tolerance test.
Glucose and insulin levels were measured at baseline and 30, 60, 90, 120, and 180 minutes after consuming the glucose.
The study results revealed that treatment with a total of 12 Generex Oral-lyn sprays resulted in a 29.6% decrease in plasma glucose at two hours and a 26.8% decrease at three hours, and an overall mean reduction in glucose levels of 15.8% was observed in the study.
The plasma insulin was also significantly increased at 30 minutes but not at 2 hours or 3 hours, which demonstrates the important increase in first phase insulin availability.
Professor Pozzilli, who led the study, said the results of this study are of particular interest because they demonstrate that Generex Oral-lyn could be successfully employed to normalize post-prandial glucose levels in subjects with IGT.
"The convenience of buccal absorption of insulin in subjects with IGT may represent a significant advantage in terms of therapeutic compliance," Pozzilli said.